Liposomes- A Nanocarrier System for Pulmonary Infection

Author: Shubhrajit Mantry, Shivani S. Mindhe, Kiran C. Mahajan, Shital Bidkar and Ganesh Dama

Download PDF

Abstract

This review studied the efficacy of liposomal dry powder inhalation for pulmonary infections. The lungs are primary organ of pulmonary system in human and most other animals The lung infection caused by various bacterias, viruses and fungus. The pneumonia is major pulmonary infection caused by some bacterias like Streptococcus pneumoniae, Staphylococcus aureus, Bacillus subtilis, E. coli, etc. The antibiotics can be administered orally, intravenously, or in other ways. On their approach to the infection site and the disease, they travel through numerous layers of tissue. Drugs can fail to perform as intended because of diverse metabolic breakdown. Because they include both hydrophilic and hydrophobic antibiotics, liposomes are amphiphilic. The Liposomes have better features than conventional drug delivery methods, including site-targeting, sustained and regulated release, protection of the drug against degradation and removal, then superior therapeutic effectiveness, and fewer harmful side effects. The size, integrity, and number of charges of liposomes are just a few of the variables that affect their stability. Several polymers are used to prevent liposome leaking.

Keywords

Antibacterial, drug delivery system, nanoliposomes, pulmonary system, vesicles

Conclusion

The liposomes are nanocarrier system which carry the encapsulated drug safely and effectively. Due to this system metabolic degradation of drug is avoids. The antibacterial drugs are encapsulate into the liposomes due to this bioavailability and drug retention time in blood is increase. The evaluation tests confirmed that the medication delivery method using carrier-based liposomes for treating pulmonary infections resulted in prolonged drug retention at the desired region and also decreased the systemic exposure. It increase the therapeutic index, decrease systemic adverse effects, lower dosage and frequency, and also reduce the cost of therapy. This work shows the liposomes can improve the treatment of the disease and prevent the emergence of drug resistance. However, research on at least two animal species, followed by clinical trials, are necessary to determine the function of liposomal formulations in the treatment of lung infection.

References

-

How to cite this article

Shubhrajit Mantry, Shivani S. Mindhe, Kiran C. Mahajan, Shital Bidkar and Ganesh Dama (2023). Liposomes- A Nanocarrier System for Pulmonary Infection. Biological Forum – An International Journal, 15(3): 675-679.